PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference BCS033047-WO	FOR FURTHER ACTION	See item 4 below
International application No. PCT/EP2004/008638	International filing date (day/month/year) 02 August 2004 (02.08.2004)	Priority date (day/month/year) 14 August 2003 (14.08.2003)
International Patent Classification (8th See relevant information in Form F	n edition unless older edition indicated) PCT/ISA/237	
Applicant BAYER CROPSCIENCE AKTIENC	GESELLSCHAFT	

1.	This international preliminary re International Searching Authorit	eport on patentability (Chapter I) is issued by the International Bureau on behalf of the ty under Rule 44 bis.1(a).
2.	This REPORT consists of a tota	of 9 sheets, including this cover sheet.
	In the attached sheets, any refere to the international preliminary	ence to the written opinion of the International Searching Authority should be read as a reference report on patentability (Chapter I) instead.
3.	This report contains indications	relating to the following items:
	Box No. I	Basis of the report
	Вох №. П	Priority
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
	Box No. IV	Lack of unity of invention
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
	Box No. VI	Certain documents cited
	Box No. VII	Certain defects in the international application
	Box No. VIII	Certain observations on the international application
4.	The International Bureau will conot, except where the applicant date (Rule 44bis .2).	ommunicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but makes an express request under Article 23(2), before the expiration of 30 months from the priority
		Date of issuance of this report 03 July 2006 (03.07.2006)

Authorized officer

e-mail: pt06@wipo.int

Agnes Wittmann-Regis

Facsimile No. +41 22 338 82 70 Form PCT/IB/373 (January 2004)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

PATENT COOPERATION TREATY

rom the		AL SEARCHIN	G AUTHOR!	ITY		346
Го:						PCT PCT
						TITTEN OPINION OF THE ONAL SEARCHING AUTHORITY
						(PCT Rule 43bis.1)
					Date of mailing (day/month/year)	
Applicar	n's or ag	gent's file referenc	e		FOR FURTHER A	ACTION
BCS	0330	47-WO				See paragraph 2 below
		plication No. 2004/0086	538	International filing date ((day/month/year)	Priority date (day/month/year) 14.08.2003
				national classification an	dIPC	
internati	onai Pai	ient Classification	(II-C) or both	mational classification an	a n c	
Applica						
BAY	ER C	CROPSCIEN	ICE AKI	TIENGESELLSC	HAFT	·
1.	This o	pinion contains in	dications relat	ting to the following item	s:	
•-	\boxtimes	Box No. I	Basis of the	•		
	\boxtimes	Box No. II	Priority			
	$\overline{\boxtimes}$	Box No. III		shment of opinion with re	gard to novelty, invent	ive step and industrial applicability
		Box No. IV		y of invention		
		Box No. V	Reasoned st	atement under Rule 43bis citations and explanatio	.1(a)(i) with regard to one supporting such state	novelty, inventive step or industrial ement
		Box No. VI		uments cited		•
		Box No. VII	Certain defe	ects in the international ap	plication	
		Box No. VIII	Certain obse	ervations on the internation	nal application	
2.	If a d Intern than th	ational Preliminar his one to be the laternational Search	y Examining IPEA and the ning Authority	Authority ("IPEA") except chosen IPEA has notified will not be so considered	pt that this does not app d the International Bur d.	Il be considered to be a written opinion of the ply where the applicant chooses an Authority other eau under Rule 66.1 bis(h) that written opinions of
	writte PCT/I	n reply together, SA/220 or before	where appropriation	priate, with amendments n of 22 months from the p	, before the expiration	A, the applicant is invited to submit to the IPEA a of 3 months from the date of mailing of Form expires later.
	For fu	rther options, see	Form PCT/IS	A/220.		
3.	For fu	rther details, see r	notes to Form	PCT/ISA/220.		
					T	
Name a	nd maili	ing address of the	ISA/EP		Authorized officer	
		•				
Facsimi	le No.				Telephone No.	

Box	No. I	Basis of this opinion
1.		regard to the language, this opinion has been established on the basis of the international application in the language in which it was unless otherwise indicated under this item.
		This opinion has been established on the basis of a translation from the original language into the following language
	_	, which is the language of a translation furnished for the purposes of international search (under
	*	Rule 12.3 and 23.1(b)).
2.		regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, this opinion has been established on the basis of:
	a.	type of material
		a sequence listing
		table(s) related to the sequence listing
	b.	format of material
		in written format
		in computer readable form
	c.	time of filing/furnishing
		contained in the international application as filed.
	•	filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Addi	tional comments:
		·

Priority	
The following document has not yet been furnished:	
copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).	
translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).	ا مه
This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found inv. Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be elevant date.	valid e the
onal observations, if necessary:	
	ł
	Ì
	translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)). consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established assumption that the relevant date in the claimed priority date. This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found in

Box No. II	I Non-establishment of opinion	with regard to novelty, inventive step and industrial applicability	
	ions whether the claimed invention ap have not been examined in respect of:	pears to be novel, to involve an inventive step (to be non obvious), or to be indu	strially
	the entire international application		
\boxtimes	claims Nos. 10 (in part), 15	and 16 (in part) (industrial applicability)	
becaus	e:		i
\boxtimes	the said international application, or the relate to the following subject matter w	e said claims Nos. 15,16 (industrial applicability) hich does not require an international preliminary examination (specify):	_
	See supplemental	•	ŀ
	See Suppremental	Sincet	
	the description, claims or drawings (in	dicate particular elements below) or said claims Nos.	
	are so unclear that no meaningful opin	ion could be formed (specify):	
	•		
		•	
		•	
	•		
	the chiese or said stoims Nos	are so inadequately supp	orted
	the claims, or said claims Nos. by the description that no meaningful		
\boxtimes	no international search report has beer	established for said claims Nos. 10 (in part)	
	the nucleotide and/or amino acid sequ Instructions in that:	ence listing does not comply with the standard provided for in Annex C of the Admini	strative
	the written form	has not been furnished	
		does not comply with the standard	
	the computer readable form	has not been furnished	
	the computer readable form	does not comply with the standard	
	the tables related to the nucleotide ar technical requirements provided for in	d/or amino acid sequence listing, if in computer readable form only, do not comply Annex C-bis of the Administrative Instructions.	with the
	See Supplemental Box for further deta		

Claims 20, 21 YES
Claims 1-19, 22-24 NO
Claims 1-19, 22-24 NO
Inventive step (IS) Claims YES Claims 19-24 NO
Claims 19-24 NO
Industrial applicability (IA) $_{ ext{Claims}}$ 1-14, 17-24, 15 and 16 (in part) YES
Claims NO
2. Citations and explanations:
1. Prior art
The following documents cited in the search report:
D1: WO 99/48869 A (WETCHOLOWSKY INGO; DREWES MARK
WILHELM (DE); ERDELEN CHRISTOPH (DE))
30 September 1999 (1999-09-30)
D2: WO 01/17973 A (WENDEBORN SEBASTIAN; MAETZKE
THOMAS (CH); SYNGENTA PARTICIPATIONS AG)
15 March 2001 (2001-03-15)
D3: WO 01/17353 A (GLOCK JUTTA; SYNGENTA
PARTICIPATIONS AG (CH)); 15 March 2001
(2001-03-15)
D4: WO 03/045957 A (DREWES MARK WILHELM; ERDELEN
CHRISTOPH (DE); FEUCHT DIETER (DE); FISC)
5 June 2003 (2003-06-05)
D5: DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR
ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE;
XP002309693 Database accession no. BRN 7957401
D6: DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR
ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE;
XP002309694 Database accession no. BRN 4968273
were taken into account in the substantive
examination.

International application No.
PCT/EP2004/008638

Box No. V

Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

2. Novelty

Claims 1-19 and 22-24 do not meet the requirements of PCT Article 33(2). The compounds (I), including all of the dependent claims, have already been described in D1. No specific definitions of variables that might be novel over D1 are apparent. The same applies to the intermediates, with the exception of those according to claim 10. The compounds according to claim 10 are, however, well known from other documents. See above, Box III. Although the compounds according to claim 9 do not appear to have been explicitly mentioned in D1, it is assumed that they are formed as intermediates in the process described on page 79, second equation. Furthermore, D1 describes components which can be added to the compounds (I). Thus, for example, page 145 mentions dicamba, which is listed in the present agent claim 19. Ultimately therefore, claims 19 and 22-24 are to be interpreted as novelty-prejudiced by D1.

3. Inventive step

The partial subject matter of present claims 19-24 which can still be regarded as novel does not, however, meet the requirements of PCT Article 33(3). D2 to D4 disclose the addition components listed in present claims 19-21. See search report for details. Since documents D2 to D4 also relate to compounds which are structurally very similar to present

International application No.
PCT/EP2004/008638

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

compounds (I) and have qualitatively equivalent properties, the agents according to the application are considered obvious.

4. Industrial applicability

The PCT Contracting States do not have uniform criteria for assessing the industrial applicability of the partial subject matter of claims 15 and 16 in their present form. Patentability may also depend on the wording of the claims. The EPO, for example, does not recognize the industrial applicability of claims to the medical use of a compound; it may, however, allow claims to the first medical application of a known compound or to the use of such a compound in the manufacture of a drug for a new medical application.

International application No.
PCT/EP2004/008638

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Box III

- 1) Claims 15 and 16 relate in part to subject matter which, in the opinion of this Authority, falls under PCT Rule 67.1(iv). Consequently no expert opinion has been established in respect of the industrial applicability of that part of the subject matter of said claims (PCT Article 34(4) (a)(i)).
- The first phase of the search on claim 10 reveals an inordinately large number of compounds prejudicial to novelty. Even when, in the selection of variables A and D, the selection made was of only unsubstituted alkyl (D also hydrogen), 30 compounds prejudicial to novelty were found, even without taking account of patent literature. The two documents D4 and D5 (see below) represent merely arbitrary references given by way of example.

Box VIII

The numbering of the last two claims ought to be 23 and 24 rather than 33 and 34 (PCT Article 6).